Ƶ

Welcome to Ƶ

Ƶ is at the forefront of enhancing the safety and efficacy of gene editing therapies to enable transformative therapeutics to become a safe reality for patients.

Updates

  • Ƶ appoints Laurence Reid and Brad Crutchfield to its Board of Directors 

    Ƶ appoints Laurence Reid and Brad Crutchfield to its Board of Directors 

    Cambridge, UK, 23 September 2024: Ƶ (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors.  Bringing extensive commercial and leadership expertise to the Board, Laurence…

    Read more

  • Ƶ appoints Steve Becker as Chief Commercial Officer 

    Ƶ appoints Steve Becker as Chief Commercial Officer 

    Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Ƶ (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive,…

    Read more

  • Ƶ and the Francis Crick Institute collaborate to advance ALS research

    Ƶ and the Francis Crick Institute collaborate to advance ALS research

    Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis Cambridge, UK,  7 May 2024: Ƶ (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has entered a research collaboration with…

    Read more

  • Ƶ appoints Gavin Burns as Vice President of Quality and Operations 

    Ƶ appoints Gavin Burns as Vice President of Quality and Operations 

    Cambridge, UK, 22 November 2023: Ƶ (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations. With an extensive background leading quality assurance in…

    Read more

  • Ƶ’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing 

    Ƶ’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing 

    Cambridge, UK, 18 October 2023: Ƶ (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing…

    Read more

  • Ƶ strengthens senior leadership team to accelerate product development

    Ƶ strengthens senior leadership team to accelerate product development

    Cambridge, UK, 02 October 2023: Ƶ (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the expansion of its senior leadership team with the appointment of Vincent Smith, PhD, as Chief Technology Officer. Bringing significant expertise in his…

    Read more

  • Ƶ Closes $15M Series A Funding Round

    Ƶ Closes $15M Series A Funding Round

    Cambridge, UK, 18 September 2023: Ƶ (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from…

    Read more

  • Ƶ joins Campus

    Ƶ joins Campus

    Cell & gene therapies based on genome editing technologies such as CRISPR-Cas9 are positioned to become a new generation of transformative therapeutics, with the ability to correct disease at the genetic level. Because they directly alter our DNA and have the propensity to go ‘off-target’, assessing whether these therapies are safe for patients is extremely…

    Read more